Abstract
Mycobacterium marinum is an atypical mycobacterium usually found in non-chlorinated water. It rarely disseminates, except in the setting of a severely immunosuppressed patient, and usually follows a sporotrichotic type of distribution.
We report the case of a 45-year-old man who had ankylosing spondylitis and was receiving infliximab and isoniazid for latent tuberculosis. The patient presented with a 5-month history of painful erythematous and suppurative nodules and abscesses on the right upper extremity. M. marinum was not isolated in cultures and histologic findings together with clinical examination provided evidence of sporotrichoid-like fish tank granuloma. The patient was treated with rifampin (rifampicin) and ethambutol for 8 months and responded satisfactorily while continuing to receive infliximab. In accordance with data in the published literature, isoniazid proved ineffective in preventing M. marinum infection in this patient.
While mycobacterial complications of tumor necrosis factor-α (TNFα) inhibitor therapy are well established, our case appears to be the first reported instance of M. marinum infection in a patient taking infliximab. As anti- TNFa agents become increasingly used for a variety of conditions, awareness of the potential infectious complications associated with use of these agents will be vital for clinicians.
Similar content being viewed by others
References
Petrini B. Mycobacterium marinum: ubiquitous agent of waterborne granulomatous skin infections. Eur J Clin Microbiol Infect Dis 2006; 25: 609–13
Aubry A, Chosidow O, Caumes E, et al. Sixty-three cases of Mycobacterium marinum infection: clinical features, treatment, and antibiotic susceptibility of causative isolates. Arch Intern Med 2002; 162: 1746–52
Bartralot R, Garcia-Patos V, Sitjas D, et al. Clinical patterns of cutaneous non-tuberculous mycobacterial infections. Br J Dermatol 2005; 152: 727–34
Mufti AH, Toye BW, Mckendry RR, et al. Mycobacterium abscessus infection after use of tumor necrosis factor alpha inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor alpha inhibitor use. Diagn Microbiol Infect Dis 2005; 53: 233–8
Clegg DO. Treatment of ankylosing spondylitis. J Rheumatol Suppl 2006; 78:24–31
Gardam MA, Keystone EC, Menzies R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis 2003; 3: 148–55
Keane J, Gershon S, Wise RP, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001; 345 (15):1098–104
Wu TS, Chiu CH, Su LH, et al. Mycobacterium marinum infection in Taiwan.J Microbiol Immunol Infect 2002; 35: 42–6
Ang P, Rattana-Apiromyakij N, Goh CL. Retrospective study of Mycobacterium marinum skin infections. Int J Dermatol 2000; 39: 343–7
Gbery IP, Djeha D, Yobouet P, et al. Atypical mycobacterial skin infections. Sante 1996; 6 (5): 317–22
Gluckman6SJ. Mycobacterium marinum. Clin Dermatol 1995; 13: 273–6
Lim YW, Chia J, Looi KP. A case report of Mycobacterium marinum infection of the hand. Singapore Med J 2000; 41: 221–3
Lahey T. Invasive Mycobacterium marinum infections. Emerg Infect Dis 2003; 9 (11): 1496–8
Harth M, Ralph ED, Faraawi R. Septic arthritis due to Mycobacterium marinum. J Rheumatol 1994; 21 (5): 957–60
Chopra N, Kirschenbaum AE, Widman D. Mycobacterium marinum tenosynovitis in a patient on etanercept therapy for rheumatoid arthritis. J Clin Rheumatol 2002; 8: 265–8
Lam A, Toma W, Schlesinger N. Mycobacterium marinum arthritis mimicking rheumatoid arthritis. J Rheumatol 2006; 33 (4): 817–9
Bresnihan B, Cunnane G. Infection complications associated with the use of biologic agents. Rheum Dis Clin North Am 2003; 29: 185–202
Peno-Green L, Lluberas G, Kingsley T, et al. Lung injury linked to etanercept therapy. Chest 2002; 122 (5): 1858–60
Phillips K, Husni ME, Karlson EW, et al. Experience with etanercept in an academic medical center: are infection rates increased? Arthritis Rheum 2002; 47 (1): 17–21
Wallis RS, Broder MS, Wong JY, et al. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004; 38 (9): 1261–5
Acknowledgments
No sources of funding were used to assist in the preparation of this case report. The authors have no conflicts of interest that are directly relevant to the content of this case report.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Rallis, E., Koumantaki-Mathioudaki, E., Frangoulis, E. et al. Severe Sporotrichoid Fish Tank Granuloma Following Infliximab Therapy. Am J Clin Dermatol 8, 385–388 (2007). https://doi.org/10.2165/00128071-200708060-00009
Published:
Issue Date:
DOI: https://doi.org/10.2165/00128071-200708060-00009